PMID- 16446016
OWN - NLM
STAT- MEDLINE
DCOM- 20061026
LR  - 20231213
IS  - 0264-410X (Print)
IS  - 0264-410X (Linking)
VI  - 24
IP  - 15
DP  - 2006 Apr 5
TI  - DNA vaccines co-expressing GP5 and M proteins of porcine reproductive and 
      respiratory syndrome virus (PRRSV) display enhanced immunogenicity.
PG  - 2869-79
AB  - The two major membrane-associated proteins of porcine reproductive and 
      respiratory syndrome virus (PRRSV), GP5 and M (encoded by ORF5 and ORF6 genes, 
      respectively), are associated as disulfide-linked heterodimers (GP5/M) in the 
      virus particle. In the present study, three different DNA vaccine constructs, 
      expressing GP5 alone (pCI-ORF5), M alone (pCI-ORF6) or GP5 and M proteins 
      simultaneously (pCI-ORF5/ORF6), were constructed. In vitro, the co-expressed GP5 
      and M proteins could form heterodimeric complexes in transfected cells and 
      heterodimerization altered the subcellular localization of GP5. The 
      immunogenicities of these DNA vaccine constructs were firstly investigated in a 
      mouse model. Mice inoculated with pCI-ORF5/ORF6 developed PRRSV-specific 
      neutralizing antibodies at 6 and 8 weeks after primary immunization. However, 
      only some mice developed low levels of neutralizing antibodies in groups 
      immunized with pCI-ORF5 or pCI-ORF6. The highest lymphocyte proliferation 
      responses were also observed in mice immunized with pCI-ORF5/ORF6. Interestingly, 
      significantly enhanced GP5-specific ELISA antibody could be detected in mice 
      immunized with pCI-ORF5/ORF6 compared to mice immunized with pCI-ORF5. The 
      immunogenicities of pCI-ORF5/ORF6 were further evaluated in piglets (the natural 
      host) and all immunized piglets developed neutralizing antibodies at 10 weeks 
      after primary immunization, whereas there was no detectable neutralizing 
      antibodies in piglets immunized with pCI-ORF5. These results indicate that the 
      formation of GP5/M heterodimers may be involved in post-translational 
      modification and transport of GP5 and may play an important role in immune 
      responses against PRRSV infection. More importantly, co-expression of GP5 and M 
      protein in heterodimers can significantly improve the potency of DNA vaccination 
      and could be used as a strategy to develop a new generation of vaccines against 
      PRRSV.
FAU - Jiang, Yunbo
AU  - Jiang Y
AD  - Laboratory of Animal Virology, College of Veterinary Medicine, Huazhong 
      Agricultural University, Wuhan 430070, Hubei, PR China.
FAU - Xiao, Shaobo
AU  - Xiao S
FAU - Fang, Liurong
AU  - Fang L
FAU - Yu, Xiaolan
AU  - Yu X
FAU - Song, Yunfeng
AU  - Song Y
FAU - Niu, Chuanshuang
AU  - Niu C
FAU - Chen, Huanchun
AU  - Chen H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060118
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Antibodies, Viral)
RN  - 0 (Luminescent Proteins)
RN  - 0 (Vaccines, DNA)
RN  - 0 (Vaccines, Synthetic)
RN  - 0 (Viral Envelope Proteins)
RN  - 0 (Viral Matrix Proteins)
RN  - 0 (Viral Vaccines)
RN  - 0 (glycoprotein 5, PRRSV)
RN  - 147336-22-9 (Green Fluorescent Proteins)
SB  - IM
MH  - Animals
MH  - Antibodies, Viral/blood
MH  - Cell Line
MH  - Cricetinae
MH  - Dimerization
MH  - Green Fluorescent Proteins/analysis/genetics
MH  - Luminescent Proteins/analysis/genetics
MH  - Lymphocytes/immunology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Microscopy, Fluorescence
MH  - Neutralization Tests
MH  - Porcine Reproductive and Respiratory Syndrome/*immunology/prevention & control
MH  - Porcine respiratory and reproductive syndrome virus/*immunology
MH  - Swine
MH  - Vaccines, DNA/genetics/*immunology
MH  - Vaccines, Synthetic/administration & dosage/immunology
MH  - Viral Envelope Proteins/genetics/*immunology
MH  - Viral Matrix Proteins/genetics/*immunology
MH  - Viral Vaccines/genetics/*immunology
MH  - Red Fluorescent Protein
EDAT- 2006/02/01 09:00
MHDA- 2006/10/27 09:00
CRDT- 2006/02/01 09:00
PHST- 2005/07/27 00:00 [received]
PHST- 2005/12/20 00:00 [revised]
PHST- 2005/12/22 00:00 [accepted]
PHST- 2006/02/01 09:00 [pubmed]
PHST- 2006/10/27 09:00 [medline]
PHST- 2006/02/01 09:00 [entrez]
AID - S0264-410X(05)01296-X [pii]
AID - 10.1016/j.vaccine.2005.12.049 [doi]
PST - ppublish
SO  - Vaccine. 2006 Apr 5;24(15):2869-79. doi: 10.1016/j.vaccine.2005.12.049. Epub 2006 
      Jan 18.